Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
Connect Biopharma Holdings (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company, has announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2024. The event will take place from September 17th to 19th in New York, NY. Connect Biopharma's management team will deliver a company presentation on September 19, 2024, at 9:10am ET at the InterContinental New York Barclay Hotel.
The presentation will be accessible via webcast, and the management team will also host one-on-one meetings during the conference. Investors interested in scheduling meetings should contact their Cantor Fitzgerald representative. Connect Biopharma will provide links to access the company presentation on their website's Investor section under Presentations & Events.
Connect Biopharma Holdings (Nasdaq: CNTB), un'azienda biopharmaceutica globale in fase clinica, ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale di Cantor Fitzgerald 2024. L'evento si svolgerà dal 17 al 19 settembre a New York, NY. Il team di gestione di Connect Biopharma presenterà un intervento aziendale il 19 settembre 2024, alle 9:10 ET presso l'InterContinental New York Barclay Hotel.
La presentazione sarà accessibile tramite webcast e il team di gestione condurrà anche incontri one-to-one durante la conferenza. Gli investitori interessati a programmare incontri dovrebbero contattare il proprio rappresentante di Cantor Fitzgerald. Connect Biopharma fornirà collegamenti per accedere alla presentazione aziendale nella sezione Investitori del loro sito web, sotto Presentazioni ed Eventi.
Connect Biopharma Holdings (Nasdaq: CNTB), una compañía biofarmacéutica global en etapa clínica, ha anunciado su participación en la Conferencia Global de Salud de Cantor Fitzgerald 2024. El evento se llevará a cabo del 17 al 19 de septiembre en Nueva York, NY. El equipo de gestión de Connect Biopharma realizará una presentación de la compañía el 19 de septiembre de 2024, a las 9:10 a.m. ET en el InterContinental New York Barclay Hotel.
La presentación será accesible a través de un webcast, y el equipo de gestión también organizará reuniones individuales durante la conferencia. Los inversores interesados en programar reuniones deben contactar a su representante de Cantor Fitzgerald. Connect Biopharma proporcionará enlaces para acceder a la presentación de la empresa en la sección de Inversores de su sitio web bajo Presentaciones y Eventos.
Connect Biopharma Holdings (Nasdaq: CNTB)는 글로벌 임상 단계의 생명공학 회사로, 2024년 칸토르 피츠제럴드 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 9월 17일부터 19일까지 뉴욕에서 개최됩니다. Connect Biopharma의 관리 팀은 2024년 9월 19일 오전 9시 10분 ET에 인터컨티넨탈 뉴욕 바클리 호텔에서 회사 발표를 진행할 예정입니다.
발표는 웹캐스트를 통해 접근이 가능하며, 관리 팀은 회의 동안 1:1 미팅도 개최할 것입니다. 미팅 일정을 잡고자 하는 투자자는 Cantor Fitzgerald 대표에게 연락해야 합니다. Connect Biopharma는 회사 발표에 접근하기 위한 링크를 웹사이트의 투자자 섹션 내 발표 및 행사에서 제공할 것입니다.
Connect Biopharma Holdings (Nasdaq: CNTB), une entreprise biopharmaceutique mondiale en phase clinique, a annoncé sa participation à la Conférence Mondiale sur la Santé de Cantor Fitzgerald 2024. L'événement aura lieu du 17 au 19 septembre à New York, NY. L'équipe de direction de Connect Biopharma fera une présentation de l'entreprise le 19 septembre 2024 à 9h10 ET à l'InterContinental New York Barclay Hotel.
La présentation sera accessible par webcast, et l'équipe de direction organisera également des réunions individuelles pendant la conférence. Les investisseurs souhaitant programmer des réunions doivent contacter leur représentant de Cantor Fitzgerald. Connect Biopharma fournira des liens pour accéder à la présentation de l'entreprise dans la section Investisseur de son site web sous Présentations et Événements.
Connect Biopharma Holdings (Nasdaq: CNTB), ein global tätiges biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der Cantor Fitzgerald Global Healthcare Conference 2024 bekannt gegeben. Die Veranstaltung findet vom 17. bis 19. September in New York, NY, statt. Das Managementteam von Connect Biopharma wird am 19. September 2024 um 9:10 Uhr ET im InterContinental New York Barclay Hotel eine Unternehmenspräsentation halten.
Die Präsentation wird über einen Webcast zugänglich sein, und das Managementteam wird während der Konferenz auch persönliche Meetings durchführen. Investoren, die Meetings planen möchten, sollten ihren Vertreter von Cantor Fitzgerald kontaktieren. Connect Biopharma wird Links zur Verfügung stellen, um auf die Unternehmenspräsentation in der Investoren-Sektion ihrer Website unter Präsentationen & Veranstaltungen zuzugreifen.
- None.
- None.
SAN DIEGO, CA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases, today announced that Connect Biopharma’s management team will participate at the Cantor Fitzgerald Global Healthcare Conference 2024 taking place in New York, NY on September 17th – September 19th. Details of the presentation are below.
Format: Company presentation
Date and time: September 19, 2024 at 9:10am ET
Location: InterContinental New York Barclay Hotel
Webcast Link: https://wsw.com/webcast/cantor22/cntb/2073357
The Connect Biopharma management team will host one-on-one meetings during the conference. Interested investors should contact their Cantor Fitzgerald representative to request meetings. Links to access company presentation for select events, when available, will be posted to Connect Biopharma’s website on the Presentations & Events page of the Investors section.
About Connect Biopharma Holdings Limited
Connect Biopharma is a global, clinical-stage biopharmaceutical company developing innovative therapies to treat inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) and has demonstrated activity in both atopic dermatitis and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and has demonstrated activity in ulcerative colitis. For more information, please visit: https://www.connectbiopharm.com/
INVESTOR CONTACT:
David Szekeres
President
dszekeres@connectpharm.com
FAQ
When and where is Connect Biopharma (CNTB) presenting at the Cantor Fitzgerald Global Healthcare Conference 2024?
How can investors access Connect Biopharma's (CNTB) presentation at the Cantor Fitzgerald conference?
What are the dates for the Cantor Fitzgerald Global Healthcare Conference 2024 that Connect Biopharma (CNTB) is attending?
Will Connect Biopharma (CNTB) be available for one-on-one meetings during the Cantor Fitzgerald conference?
